Goldman Sachs’s BioTelemetry, Inc. BEAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-208,944
| Closed | -$15.1M | – | 6600 |
|
|
2020
Q4 | $15.1M | Buy |
208,944
+87,666
| +72% | +$4.59M | ﹤0.01% | 2097 |
|
|
2020
Q3 | $5.53M | Sell |
121,278
-29,355
| -19% | -$1.23M | ﹤0.01% | 2817 |
|
|
2020
Q2 | $6.81M | Sell |
150,633
-63,245
| -30% | -$2.83M | ﹤0.01% | 2565 |
|
|
2020
Q1 | $8.24M | Buy |
213,878
+75,269
| +54% | +$3.47M | ﹤0.01% | 2230 |
|
|
2019
Q4 | $6.42M | Buy |
138,609
+30,811
| +29% | +$1.33M | ﹤0.01% | 2762 |
|
|
2019
Q3 | $4.39M | Sell |
107,798
-55,190
| -34% | -$2.38M | ﹤0.01% | 2958 |
|
|
2019
Q2 | $7.85M | Sell |
162,988
-156,284
| -49% | -$8.22M | ﹤0.01% | 2542 |
|
|
2019
Q1 | $20M | Buy |
319,272
+62,821
| +24% | +$4.32M | 0.01% | 1864 |
|
|
2018
Q4 | $15.3M | Buy |
256,451
+67,025
| +35% | +$4.02M | ﹤0.01% | 2019 |
|
|
2018
Q3 | $12.2M | Buy |
189,426
+5,667
| +3% | +$316K | ﹤0.01% | 2297 |
|
|
2018
Q2 | $8.27M | Buy |
183,759
+93,834
| +104% | +$3.74M | ﹤0.01% | 2555 |
|
|
2018
Q1 | $2.79M | Buy |
89,925
+10,191
| +13% | +$335K | ﹤0.01% | 3341 |
|
|
2017
Q4 | $2.38M | Sell |
79,734
-46,855
| -37% | -$1.36M | ﹤0.01% | 3635 |
|
|
2017
Q3 | $4.18M | Buy |
126,589
+64,037
| +102% | +$2.22M | ﹤0.01% | 3327 |
|
|
2017
Q2 | $2.09M | Sell |
62,552
-13,358
| -18% | -$398K | ﹤0.01% | 3802 |
|
|
2017
Q1 | $2.2M | Sell |
75,910
-27,564
| -27% | -$683K | ﹤0.01% | 3657 |
|
|
2016
Q4 | $2.31M | Buy |
103,474
+41,384
| +67% | +$809K | ﹤0.01% | 3717 |
|
|
2016
Q3 | $1.15M | Buy |
62,090
+50,545
| +438% | +$953K | ﹤0.01% | 4279 |
|
|
2016
Q2 | $188K | Sell |
11,545
-836
| -7% | -$12.3K | ﹤0.01% | 5741 |
|
|
2016
Q1 | $145K | Sell |
12,381
-907
| -7% | -$10.1K | ﹤0.01% | 5857 |
|
|
2015
Q4 | $155K | Buy |
13,288
+3,016
| +29% | +$38.2K | ﹤0.01% | 5888 |
|
|
2015
Q3 | $126K | Sell |
10,272
-4,051
| -28% | -$51.6K | ﹤0.01% | 6333 |
|
|
2015
Q2 | $135K | Buy |
+14,323
| New | +$133K | ﹤0.01% | 6441 |
|
|
2015
Q1 | – | Sell |
-58,953
| Closed | -$591K | – | 7600 |
|
|
2014
Q4 | $591K | Buy |
+58,953
| New | +$506K | ﹤0.01% | 5131 |
|
|
2014
Q3 | – | Sell |
-19,819
| Closed | -$142K | – | 7513 |
|
|
2014
Q2 | $142K | Buy |
19,819
+4,204
| +27% | +$33.5K | ﹤0.01% | 6410 |
|
|
2014
Q1 | $158K | Buy |
15,615
+1,279
| +9% | +$11.8K | ﹤0.01% | 6216 |
|
|
2013
Q4 | $114K | Sell |
14,336
-4,367
| -23% | -$40.8K | ﹤0.01% | 6233 |
|
|
2013
Q3 | $185K | Buy |
18,703
+8,568
| +85% | +$67.4K | ﹤0.01% | 5919 |
|
|
2013
Q2 | $60K | Buy |
+10,135
| New | +$34.1K | ﹤0.01% | 6011 |
|
Other funds holding BEAT
Goldman Sachs's BEAT Position: Q1 2021 in Review
Goldman Sachs sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 208,944 shares — an estimated $15.1M sold.
Goldman Sachs first reported a position in BEAT in Q2 2013 and held it in 29 quarters. The position peaked at $20M in Q1 2019. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.
- Goldman Sachs reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
- Goldman Sachs sold 208,944 BioTelemetry, Inc. shares in Q1 2021, an estimated $15.1M.
- Goldman Sachs first reported a position in BioTelemetry, Inc. in Q2 2013 and held it in 29 quarters.
- Goldman Sachs's BioTelemetry, Inc. position peaked at $20M in Q1 2019.
- 1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.
Based on Goldman Sachs's 13F filing for Q1 2021, filed 17 May 2021.